Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)
China flag China · Delayed Price · Currency is CNY
59.32
-1.76 (-2.88%)
Nov 17, 2026, 4:00 PM EST

SHA:688192 Financials Overview

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
4,984801.14359.991.29-10.29
Revenue Growth
720.14%122.60%294.25%---62.95%
Gross Profit
4,938766.91350.5883.63-3.65-2.65
Operating Income
3,407-819.97-972.43-1,155-792.55-674.37
Net Income
3,455-764.05-845.96-1,108-736-669.88
Earnings Per Share
7.42-1.71-2.04-2.72-1.82-1.86
EPS Growth
------

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
5,5871,936839.99748.21,4162,075
Total Debt
1,2911,2411,157410.3785.2787.76
Net Cash (Debt)
4,296695.51-317.39337.831,3311,987
Net Cash Growth
397.18%---74.62%-33.02%231.62%
Net Cash Per Share
9.221.56-0.770.833.295.52

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
3,485-588.32-650.53-967.88-603.37-492.28
Capital Expenditures
-70.19-170.47-137.58-32.13-73.78-8.98
Free Cash Flow
3,415-758.79-788.1-1,000-677.15-501.26
Free Cash Flow Growth
------

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
99.08%95.73%97.41%91.61%--25.72%
Operating Margin
68.36%-102.35%-270.19%-1265.43%--6556.55%
Pretax Margin
69.23%-95.75%-261.09%-1213.31%--6512.85%
Profit Margin
69.31%-95.37%-235.05%-1213.42%--6512.85%
FCF Margin
68.51%-94.72%-218.98%-1095.44%--4873.51%

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
5.5433.1647.89213.94-1454.37